| Groups |
Subtypes and stages |
Subjects |
BMI1 expression |
p |
| Number |
|
Median |
Range |
Total AML
N=100 |
Total |
100 |
100 |
4.4 |
0.02-8.90 |
<0.001 |
| M0 |
2 |
2.0 |
5.90 |
4.20-7.60 |
<0.001 |
| M1 |
14 |
14.0 |
4.45 |
1.80-6.80 |
<0.001 |
| M2 |
28 |
28.0 |
3.70 |
1.40-8.90 |
<0.001 |
| M4 |
31 |
31.0 |
4.50 |
0.02-7.60 |
<0.001 |
| M5 |
18 |
18.0 |
4.80 |
0.19-8.90 |
<0.001 |
| M6 |
7 |
7.0 |
3.40 |
0.78-8.90 |
<0.001 |
Total CML
N=100 |
Total |
100 |
100 |
2.5 |
0.87-7.60 |
<0.001 |
| Chronic phase |
66 |
66.0 |
2.10 |
0.87-4.10 |
<0.001 |
| accelerated phase |
20 |
20.0 |
3.40 |
1.70-7.60 |
<0.001 |
| Blastic phase |
14 |
14.0 |
4.20 |
1.40-5.60 |
<0.001 |
| Control |
20 |
100.0 |
0.13 |
0.02-0.19 |
- |
|
| P: Significance versus Control. Significance of accelerated versus chronic:p<0.001, blastic versus chronic: p<0.001, blastic versus accelerated: p=0.332 |
| Table 1: BMI1 expression level in myeloid leukemias. |
